# Strata Critical Medical, Inc.: financial statements, quarterly

SRTA · Nasdaq · CIK 1779128 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srta.md) · [Financials](/companies/srta/financials.md) · [Filings](/companies/srta/filings.md) · [Insiders](/companies/srta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [71.4](/filings/0001779128-24-000126.md) | [47.5 d](/filings/0001779128-25-000010.md) | [51.5](/filings/0001779128-25-000042.md) | [67.9](/filings/0001779128-25-000060.md) | [36.1](/filings/0001628280-25-050870.md) | [36.4 d](/filings/0001628280-26-013628.md) | [35.9](/filings/0001628280-26-031032.md) | [45.1](/filings/0001628280-26-052256.md) | [49.3](/filings/0001628280-25-050870.md) | [66.8 d](/filings/0001628280-26-013628.md) | [67.4](/filings/0001628280-26-031032.md) | [72.5](/filings/0001628280-26-052256.md) |
| Cost of revenue | $m | [55.9](/filings/0001779128-24-000126.md) | [38.5 d](/filings/0001779128-25-000010.md) | [41.4](/filings/0001779128-25-000042.md) | [51.6](/filings/0001779128-25-000060.md) | [28.6](/filings/0001628280-25-050870.md) | [31.4 d](/filings/0001628280-26-013628.md) | [28.9](/filings/0001628280-26-031032.md) | [36.1](/filings/0001628280-26-052256.md) | [37.7](/filings/0001628280-25-050870.md) | [55.1 d](/filings/0001628280-26-013628.md) | [53.3](/filings/0001628280-26-031032.md) | [57.3](/filings/0001628280-26-052256.md) |
| Gross profit | $m | [15.6](/filings/0001779128-23-000121.md) | not reported | not reported | not reported | not reported | not reported | [7.1](/filings/0001628280-26-031032.md) | [9.0](/filings/0001628280-26-052256.md) | not reported | not reported | [14.1](/filings/0001628280-26-031032.md) | [15.2](/filings/0001628280-26-052256.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [12.3](/filings/0001628280-26-031032.md) | [13.3](/filings/0001628280-26-052256.md) | not reported | not reported | [15.6](/filings/0001628280-26-031032.md) | [14.0](/filings/0001628280-26-052256.md) |
| Operating income | $m | [(7.4)](/filings/0001779128-24-000126.md) | [(35.6) d](/filings/0001779128-25-000010.md) | [(9.9)](/filings/0001779128-25-000042.md) | [(12.1)](/filings/0001779128-25-000060.md) | [(7.1)](/filings/0001628280-25-050870.md) | [(5.9) d](/filings/0001628280-26-013628.md) | [(5.7)](/filings/0001628280-26-031032.md) | [(4.6)](/filings/0001628280-26-052256.md) | [(5.6)](/filings/0001628280-25-050870.md) | [(6.4) d](/filings/0001628280-26-013628.md) | [(3.0)](/filings/0001628280-26-031032.md) | [(5.4)](/filings/0001628280-26-052256.md) |
| Income tax | $m | [0.1](/filings/0001779128-24-000126.md) | [(1.0) d](/filings/0001779128-25-000010.md) | [(0.1)](/filings/0001779128-25-000042.md) | [0.1](/filings/0001779128-25-000060.md) | [0.0](/filings/0001628280-25-050870.md) | [0.0 d](/filings/0001628280-26-013628.md) | [0.0](/filings/0001628280-26-031032.md) | [0.0](/filings/0001628280-26-052256.md) | [0.0](/filings/0001628280-25-050870.md) | [0.0 d](/filings/0001628280-26-013628.md) | [0.0](/filings/0001628280-26-031032.md) | [0.0](/filings/0001628280-26-052256.md) |
| Net income | $m | [0.3](/filings/0001779128-24-000126.md) | [(33.9) d](/filings/0001779128-25-000010.md) | [(4.2)](/filings/0001779128-25-000042.md) | [(11.3)](/filings/0001779128-25-000060.md) | [(2.0)](/filings/0001628280-25-050870.md) | [(9.8) d](/filings/0001628280-26-013628.md) | [(3.5)](/filings/0001628280-26-031032.md) | [(3.7)](/filings/0001628280-26-052256.md) | [57.4](/filings/0001628280-25-050870.md) | [(8.8) d](/filings/0001628280-26-013628.md) | [2.2](/filings/0001628280-26-031032.md) | [(10.5)](/filings/0001628280-26-052256.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001779128-24-000126.md) | not reported | [(0.06)](/filings/0001779128-25-000042.md) | [(0.15)](/filings/0001779128-25-000060.md) | [(0.03)](/filings/0001628280-25-050870.md) | not reported | [(0.04)](/filings/0001628280-26-031032.md) | [(0.05)](/filings/0001628280-26-052256.md) | [0.70](/filings/0001628280-25-050870.md) | not reported | [0.03](/filings/0001628280-26-031032.md) | [(0.12)](/filings/0001628280-26-052256.md) |
| Basic EPS | $ per share | [0.00](/filings/0001779128-24-000126.md) | not reported | [(0.06)](/filings/0001779128-25-000042.md) | [(0.15)](/filings/0001779128-25-000060.md) | [(0.03)](/filings/0001628280-25-050870.md) | not reported | [(0.04)](/filings/0001628280-26-031032.md) | [(0.05)](/filings/0001628280-26-052256.md) | [0.70](/filings/0001628280-25-050870.md) | not reported | [0.03](/filings/0001628280-26-031032.md) | [(0.12)](/filings/0001628280-26-052256.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [36.8](/filings/0001779128-24-000126.md) | [27.9](/filings/0001779128-25-000010.md) | [36.8](/filings/0001779128-25-000042.md) | [26.3](/filings/0001779128-25-000060.md) | [20.0](/filings/0001628280-25-050870.md) | [18.4](/filings/0001628280-26-013628.md) | [34.8](/filings/0001628280-26-031032.md) | [58.8](/filings/0001628280-26-052256.md) | [22.8](/filings/0001628280-25-050870.md) | [31.0](/filings/0001628280-26-013628.md) | [58.7](/filings/0001628280-26-031032.md) | [16.3](/filings/0001628280-26-052256.md) |
| Current assets | $m | [209](/filings/0001779128-23-000121.md) | [206](/filings/0001779128-25-000010.md) | [194](/filings/0001779128-24-000068.md) | [183](/filings/0001779128-24-000097.md) | [172](/filings/0001779128-24-000126.md) | [161](/filings/0001628280-26-013628.md) | [152](/filings/0001779128-25-000042.md) | [156](/filings/0001779128-25-000060.md) | [122](/filings/0001628280-25-050870.md) | [126](/filings/0001628280-26-052256.md) | [124](/filings/0001628280-26-031032.md) | [121](/filings/0001628280-26-052256.md) |
| Total assets | $m | [318](/filings/0001779128-23-000121.md) | [295](/filings/0001779128-25-000010.md) | [283](/filings/0001779128-24-000068.md) | [280](/filings/0001779128-24-000097.md) | [283](/filings/0001779128-24-000126.md) | [257](/filings/0001628280-26-013628.md) | [251](/filings/0001779128-25-000042.md) | [258](/filings/0001779128-25-000060.md) | [335](/filings/0001628280-25-050870.md) | [325](/filings/0001628280-26-052256.md) | [328](/filings/0001628280-26-031032.md) | [333](/filings/0001628280-26-052256.md) |
| Current liabilities | $m | [30.4](/filings/0001779128-23-000121.md) | [35.5](/filings/0001779128-25-000010.md) | [23.2](/filings/0001779128-24-000068.md) | [30.3](/filings/0001779128-24-000097.md) | [27.2](/filings/0001779128-24-000126.md) | [22.7](/filings/0001628280-26-013628.md) | [21.9](/filings/0001779128-25-000042.md) | [26.3](/filings/0001779128-25-000060.md) | [27.9](/filings/0001628280-25-050870.md) | [19.8](/filings/0001628280-26-052256.md) | [20.9](/filings/0001628280-26-031032.md) | [45.8](/filings/0001628280-26-052256.md) |
| Total liabilities | $m | [54.6](/filings/0001779128-23-000121.md) | [60.6](/filings/0001779128-25-000010.md) | [46.2](/filings/0001779128-24-000068.md) | [50.9](/filings/0001779128-24-000097.md) | [49.4](/filings/0001779128-24-000126.md) | [34.7](/filings/0001628280-26-013628.md) | [30.8](/filings/0001779128-25-000042.md) | [34.8](/filings/0001779128-25-000060.md) | [52.1](/filings/0001628280-25-050870.md) | [46.4](/filings/0001628280-26-052256.md) | [41.9](/filings/0001628280-26-031032.md) | [53.4](/filings/0001628280-26-052256.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [263](/filings/0001779128-24-000126.md) | [234](/filings/0001628280-26-013628.md) | [237](/filings/0001779128-25-000060.md) | [229](/filings/0001628280-25-050870.md) | [233](/filings/0001628280-25-050870.md) | [222](/filings/0001628280-26-052256.md) | [220](/filings/0001628280-26-052256.md) | [223](/filings/0001628280-26-052256.md) | [283](/filings/0001628280-25-050870.md) | [279](/filings/0001628280-26-052256.md) | [286](/filings/0001628280-26-052256.md) | [279](/filings/0001628280-26-052256.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2.0 d](/filings/0001779128-24-000126.md) | [(9.3) d](/filings/0001779128-25-000010.md) | [(15.6)](/filings/0001779128-25-000042.md) | [8.4 d](/filings/0001779128-25-000060.md) | [6.4 d](/filings/0001628280-25-050870.md) | [(1.8) d](/filings/0001628280-26-013628.md) | [(0.2)](/filings/0001628280-26-031032.md) | [(3.1) d](/filings/0001628280-26-052256.md) | [(37.3) d](/filings/0001628280-25-050870.md) | [(8.3) d](/filings/0001628280-26-013628.md) | [3.9](/filings/0001628280-26-031032.md) | [5.7 d](/filings/0001628280-26-052256.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001779128-24-000126.md) | [0.0 d](/filings/0001779128-25-000010.md) | [0.8](/filings/0001779128-25-000042.md) | [16.2 d](/filings/0001779128-25-000060.md) | [9.3 d](/filings/0001628280-25-050870.md) | [4.6 d](/filings/0001628280-26-013628.md) | [2.6](/filings/0001628280-26-031032.md) | [2.2 d](/filings/0001628280-26-052256.md) | [2.9 d](/filings/0001628280-25-050870.md) | [1.8 d](/filings/0001628280-26-013628.md) | [5.2](/filings/0001628280-26-031032.md) | [2.5 d](/filings/0001628280-26-052256.md) |
| Share repurchases | $m | [0.0 d](/filings/0001779128-24-000126.md) | [0.0 d](/filings/0001779128-25-000010.md) | not reported | not reported | [0.0 d](/filings/0001628280-25-050870.md) | [0.0 d](/filings/0001628280-26-013628.md) | not reported | not reported | [0.0 d](/filings/0001628280-25-050870.md) | [0.0 d](/filings/0001628280-26-013628.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [71.5](/filings/0001779128-23-000121.md) | [72.0](/filings/0001779128-24-000068.md) | [73.2](/filings/0001779128-24-000097.md) | [81.0](/filings/0001779128-24-000126.md) | [75.8](/filings/0001779128-25-000042.md) | [77.6](/filings/0001779128-25-000060.md) | [78.0](/filings/0001628280-25-050870.md) | [79.9](/filings/0001628280-26-031032.md) | [81.3](/filings/0001628280-26-052256.md) | [82.5](/filings/0001628280-25-050870.md) | [90.2](/filings/0001628280-26-031032.md) | [86.2](/filings/0001628280-26-052256.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,466,806 at 2026-07-28, from the cover of the [10-Q filed 2026-08-04](/filings/0001628280-26-052256.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.